• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
【24h】

2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.

机译：2009年5型磷酸二酯酶抑制剂治疗的更新：第2部分：针对此类中的性问题和罕见毒性的最佳利用方法的更新。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Highly selective inhibitors of phosphodiesterase type 5 (PDE5I) have been commercially available for over a decade. Our knowledge of these drugs continues to expand. AIMS: To review recent (since 2007) developments on the utilization of PDE5I in clinical practice. The focus of this manuscript is on the use of PDE5I for sexual concerns. Also reviewed are recent reports of rare but potentially serious toxicity. METHODS: Pubmed search utilizing the search terms phosphodiesterase type 5 inhibitor, vardenafil, clinical practice of sexual medicine and/or PDE5I toxicity. Publications on routine dose PDE5I for penile rehabilitation, lower urinary tract symptoms, and stuttering priapism are summarized in a separate manuscript in this series. MAIN OUTCOME MEASURES: Peer-reviewed publications since the last major update on PDE5I published in the medical literature. RESULTS: Recent investigations have suggested a number of interventions to potentially improve patient compliance with PDE5I therapy. Additionally, the approval in the past year of tadalafil as a daily medication signifies a potential paradigm shift in our concept of this disorder. Daily dosing may be useful in some men; however, the other available PDE5I continue to show excellent efficacy in the management of erectile dysfunction (ED). In addition to direct effects on ED, several recent reports highlight the use of PDE5I for improvement of premature ejaculation, sexual relationship status, and sexual function in women. There have also been several recent reports of rare but serious toxicity, particularly ototoxicity, associated with PDE5I use. CONCLUSIONS: Recent studies have suggested new ways to optimize utilization of PDE5I not only for the management of ED but also for other sexual concerns in both men and women. Rare but serious toxicities have been reported with PDE5I and, therefore, judicious counseling is indicated before prescribing these medications.
机译：简介：高度选择性的5型磷酸二酯酶抑制剂（PDE5I）已在市场上销售了十多年。我们对这些药物的了解在不断扩大。目的：回顾最近（自2007年以来）在临床实践中使用PDE5I的进展。该手稿的重点是针对性问题使用PDE5I。还回顾了罕见但潜在的严重毒性的最新报道。方法：采用搜索词5型磷酸二酯酶抑制剂，伐地那非，性医学的临床实践和/或PDE5I毒性进行公开搜索。本系列的另一篇手稿中概述了用于阴茎康复，下尿路症状和口吃性阴茎异常勃勃的常规剂量PDE5I的出版物。主要观察指标：自从医学文献中发表有关PDE5I的最新重大更新以来，经过同行评审的出版物。结果：最近的调查表明，有许多干预措施可以潜在地改善患者对PDE5I治疗的依从性。此外，他达拉非在过去一年中被批准为日常用药，这标志着我们对这种疾病概念的潜在转变。每日剂量可能对某些男性有用;但是，其他可用的PDE5I在勃起功能障碍（ED）的治疗中继续显示出优异的疗效。除了对ED的直接影响外，最近的一些报道还强调了使用PDE5I改善妇女的早泄，性关系状况和性功能。最近也有几篇关于使用PDE5I的罕见但严重的毒性特别是耳毒性的报道。结论：最近的研究提出了新的方法来优化PDE5I的利用率，不仅可以用于ED的管理，还可以解决男性和女性的其他性问题。据报道，PDE5I罕见但有严重毒性，因此，在开这些药物之前应给予明智的咨询。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号